Search Results - Gaia Gallo

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses by Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg

Connect to this object online.

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3 by Alexander Egeberg, Lars Erik Kristensen, Ronald Vender, Shirin Zaheri, Celine El Baou, Gaia Gallo, Elisabeth Riedl, Christopher Schuster

Connect to this object online.

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S) by Norman Wasel, Diamant Thaçi, Lars E. French, Curdin Conrad, Yves Dutronc, Gaia Gallo, Lovisa Berggren, Jean-Philippe Lacour

Connect to this object online.

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by... by Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong

Connect to this object online.

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... by Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong

Connect to this object online.

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment by Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer

Connect to this object online.

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment by Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer

Connect to this object online.

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure by April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl

Connect to this object online.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

Connect to this object online.